

Special Issue

State of the Art in Mitral Valve Disease

Message from the Guest Editor

Mitral valve disease is among the most prevalent valvular disorders, posing a significant challenge due to its high mortality and morbidity rates, especially as the global population ages. Surgery remains the gold standard for treating primary mitral valve disease, and the debate is still going on with standard approaches as opposed to minimally invasive approaches, especially when dealing with long-term results. Percutaneous mitral valve repair and replacement are real noninvasive techniques and have demonstrated promising outcomes. Each treatment needs to be discussed with its pro and cons detailed. This Special Issue will focus on the latest innovations in mitral valve disease management, from novel imaging modalities for early diagnosis to cutting-edge surgical and micro-invasive therapies. It will also highlight the evolving roles of cardiac anesthesiologists, intensivists, and cardiologists in perioperative care, which are increasingly important in achieving optimal patient outcomes.

Guest Editor

Prof. Dr. Gilles D. Dreyfus

Department of Cardiac Surgery, Hôpital Européen Georges Pompidou, 75015 Paris, France

Deadline for manuscript submissions

closed (31 December 2025)



Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/219255

*Journal of Cardiovascular
Development and Disease*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease (JCDD, ISSN 2308-3425)* is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to *JCDD* undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. *JCDD* guarantees fast dissemination of results to a large scientific audience.

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q2 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 24.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).